Emergent BioSolutions's Single-Dose Chikungunya Vaccine Candidate Effective Even After Two Years of Vaccination

Emergent BioSolutions Inc EBS has announced two-year persistence data from its Phase 2 study evaluating its investigational chikungunya virus, virus-like particle (CHIKV VLP) vaccine candidate.
The CHIKV VLP vaccine is the only single-dose VLP-based vaccine currently in clinical development for active immunization against chikungunya disease, the company said.
Two years post-vaccination, serum neutralizing antibodies (SNA) responses were 19 times higher than pre-vaccination titers following a single adjuvanted 40 µg dose.
All subjects in the single-dose regimen remained seropositive at their one-year and two-year visits.
The vaccine candidate was well-tolerated, and no significant vaccine-related safety concerns were identified.
The majority of solicited adverse events were mild or moderate, and the most frequent were local injection site pain.
The company will publish the results of this study in the near term.
The CHIKV VLP vaccine candidate received the FDA Fast Track designation in May 2018 and EMA PRIME designation in September 2019.
Chikungunya virus is spread to people by infected mosquitoes.
Price Action: EBS shares are up 2.44% at $57.99 in the premarket session on the last check Wednesday.